These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15510621)

  • 1. Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study.
    Stokman MA; Wachters FM; Koopmans P; Burgerhof JG; Groen HJ; Spijkervet FK; Uges DR; Hospers GA
    Anticancer Res; 2004; 24(5B):3263-7. PubMed ID: 15510621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
    Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
    Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
    Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
    Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
    Wachters FM; Van Putten JW; Kramer H; Erjavec Z; Eppinga P; Strijbos JH; de Leede GP; Boezen HM; de Vries EG; Groen HJ
    Br J Cancer; 2003 Oct; 89(7):1192-9. PubMed ID: 14520444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
    Senzer N
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):38-41. PubMed ID: 12577242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer.
    Patlakas G; Bouros D; Tsantekidou-Pozova S; Koukourakis MI
    Anticancer Res; 2005; 25(2B):1427-31. PubMed ID: 15865101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.
    Stokman MA; Spijkervet FK; Boezen HM; Schouten JP; Roodenburg JL; de Vries EG
    J Dent Res; 2006 Aug; 85(8):690-700. PubMed ID: 16861284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.
    Phan TP; Crane CH; Janjan NA; Vrdoljak E; Milas L; Mason KA
    Int J Pancreatol; 2001; 29(1):19-23. PubMed ID: 11558629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of oral mucositis during local radiation and systemic chemotherapy: a study of 98 patients.
    Carl W; Emrich LS
    J Prosthet Dent; 1991 Sep; 66(3):361-9. PubMed ID: 1800734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis.
    Wymenga AN; van der Graaf WT; Hofstra LS; Spijkervet FK; Timens W; Timmer-Bosscha H; Sluiter WJ; van Buuren AH; Mulder NH; de Vries EG
    Clin Cancer Res; 1999 Jun; 5(6):1363-8. PubMed ID: 10389920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
    Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new in vitro assay for quantitation of chemotherapy-induced mucositis.
    Wymenga AN; van der Graaf WT; Spijkervet FL; Timens W; Timmer-Bosscha H; Sluiter WJ; de Vries EG; Mulder NH
    Br J Cancer; 1997; 76(8):1062-6. PubMed ID: 9376267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S; Hoffmanns H
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
    Haigentz M; Kim M; Sorich J; Lee J; Hochster H; Macapinlac M; Mirchandani D; Sewak S; Pavlick A; Volm M; Hamilton A; Muggia FM
    Anticancer Drugs; 2003 Apr; 14(4):321-6. PubMed ID: 12679737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
    Chi KH; Chen CH; Chan WK; Chow KC; Chen SY; Yen SH; Chao JY; Chang CY; Chen KY
    J Clin Oncol; 1995 Oct; 13(10):2620-8. PubMed ID: 7595716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
    Yardley DA; Peacock NW; Dickson NR; White MB; Vázquez ER; Foust JT; Grapski R; Hendricks LK; Scott WL; Hainsworth JD
    Clin Breast Cancer; 2010 Jun; 10(3):217-23. PubMed ID: 20497920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.